Patents by Inventor Vincent J. Miles

Vincent J. Miles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7432047
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 7, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 7285383
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: October 23, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 7045284
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: May 16, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Publication number: 20040254140
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: June 14, 2004
    Publication date: December 16, 2004
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6824976
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 30, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6777179
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: August 17, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6667152
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: December 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6623961
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: September 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Publication number: 20030144226
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 27, 2002
    Publication date: July 31, 2003
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6579674
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: June 17, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Publication number: 20020165194
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 28, 2002
    Publication date: November 7, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Publication number: 20020160976
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 31, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Publication number: 20020160977
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 28, 2002
    Publication date: October 31, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6410715
    Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: June 25, 2002
    Assignees: Questcor Pharmaceuticals, Inc., Mc Gill University
    Inventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
  • Patent number: 6156496
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: December 5, 2000
    Assignee: Ribogene, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6111077
    Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: August 29, 2000
    Assignees: RiboGene, Inc., McGill University
    Inventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
  • Patent number: 5874231
    Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder. The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: February 23, 1999
    Assignees: McGill University, Ribogene, Inc.
    Inventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
  • Patent number: 5738985
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: April 14, 1998
    Assignee: Ribogene, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze